Description
Founded in 1998, Nextech Invest is a venture capital firm based in Zurich, Switzerland. The firm prefers to invest in the life science, biotechnology, and oncology sector.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Flare Therapeutics | 22-Mar-2023 | Early Stage VC | 00000 | Drug Discovery | Pre-Clinical Trials | 00000 00000 00.0 |
0000000 000 | 13-Feb-2023 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | 00000 00000 00.0 |
0000000000 0000000 | 08-Nov-2022 | 000000000000 | 00000 | Biotechnology | Clinical Trials - Phase 1 | 00000 000000000 00.0 |
00000000 000000000 | 30-Sep-2022 | 00000 00000 | 000.00 | Biotechnology | Generating Revenue | 00000 000000000 00.0 |
00000 0 0000000000 | 30-Jun-2022 | 00000 00000 | 0000 | Biotechnology | Pre-Clinical Trials | 0000000 000000000 00.0 |
0000 000000000000 | 09-May-2022 | 00000 00000 | 00000 | Drug Discovery | Startup | 00000 000000000 00.0 |
0000 | 28-Apr-2022 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | |
000000 000000 | 22-Mar-2022 | 00000 00000 | 000.00 | Drug Discovery | Pre-Clinical Trials | 00000 000000000 00.0 |
Alterome Therapeutics | 19-Jan-2022 | Early Stage VC | 000.00 | Biotechnology | Generating Revenue | 00000 000000000 00.0 |
Ambagon Therapeutics | 05-Jan-2022 | Early Stage VC | 0000 | Drug Discovery | Generating Revenue | 0000000 000000000 00.0 |
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
EQRx | 17-Dec-2021 | Reverse Merger | 00.00 |
0000 00000000000 | 15-Sep-2021 | 000 | 00000 |
00000000 000000000 | 01-Aug-2021 | 000000000000000000 | 00.00 |
00000000 00000000 | 08-Jan-2021 | 000 | 00000 |
0000000000 0000000 | 04-Dec-2020 | 000 | 00000 |
0000000 000000000 | 03-Dec-2020 | 000 | 00000 |
000000 000 | 09-Oct-2020 | 000 | 00000 |
00 000000000000 | 02-Oct-2020 | 000 | 00000 |
PMV Pharma | 25-Sep-2020 | IPO | 00000 |
Revolution Medicines | 13-Feb-2020 | IPO | 00000 |
Name | Title | Deals | Funds | Boards | Office |
---|---|---|---|---|---|
Marco Weibel | Chief Financial Officer | Zurich, Switzerland | |||
Rocco Sgobbo | Managing Partner & Chief Operating Officer | Zurich, Switzerland | |||
Alfred Scheidegger Ph.D | Founder & Managing Partner | 0 | 0 | Zurich, Switzerland | |
Jakob Loven Ph.D | Managing Partner | 00 | 0 | 0 | Zurich, Switzerland |
Thilo Schroeder Ph.D | Managing Partner | 00 | 0 | 0 | Zurich, Switzerland |
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
Casdin Capital | 13 | 0 | 0 |
![]() |
![]() |
Boxer Capital | 00 | 0 | 0 |
![]() |
![]() |
RA Capital Management | 00 | 0 | 00 |
![]() |
![]() |
Logos Capital | 0 | 0 | 0 |
![]() |
![]() |
BVF Partners | 0 | 0 | 0 |
![]() |
![]() |